Amylyx Pharmaceuticals, Inc. Employee Count
The employee counts Amylyx Pharmaceuticals, Inc. states in its annual reports on SEC EDGAR, each as filed.
- 2025-12-31: Employees (as filed) 136; Filing 2026-03-03.
- 2024-12-31: Employees (as filed) 123; Filing 2025-03-04; Lease expense per employee $17,682.93.
- 2023-12-31: Employees (as filed) 384; Filing 2024-02-22; Lease expense per employee $5,664.06.
- 2022-12-31: Employees (as filed) 262; Filing 2023-03-13; Lease expense per employee $8,152.67.
- Available history
- 2021-12-31 to 2025-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2025-12-31 | 136 full-time | 2026-03-03 | |
| 2024-12-31 | 123 full-time | 2025-03-04 | $17,682.93 total lease cost |
| 2023-12-31 | 384 full-time | 2024-02-22 | $5,664.06 total lease cost |
| 2022-12-31 | 262 full-time | 2023-03-13 | $8,152.67 total lease cost |
| 2021-12-31 | 205 full-time | 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |